Ipca Laboratories (IPCALAB) Share Price falls 2.06% as stock trades at Rs 1,929
- September 28, 2026
- Posted by: Harsh Piplani
- Category: News
Ipca Laboratories Share Price declined to Rs 1,929 on 28 September 2026, down 2.06% from the previous close, with the company valued at a market capitalisation of Rs 49,967.05 crore. The move places Ipca Laboratories in focus for today’s stock news because the session shows a clear same-day price fall, even though the supplied data does not establish a company-specific catalyst. For investors tracking Ipca Laboratories Share Price Today, the event is best read as a market update backed by measurable price action, valuation metrics and healthcare sector comparisons rather than a narrative about a confirmed trigger. Univest is following the stock with a focus on the exact numbers that matter most for share price analysis, fundamental analysis and relative positioning inside pharmaceuticals.
Ipca Laboratories (IPCALAB) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,929 |
| Previous Close | Rs 1,969.5 |
| Today's Move | -Rs 40.50 (-2.06%) |
| Open | Rs 1,959.75 |
| High | Rs 1,972.95 |
| Low | Rs 1,927.7 |
| Turnover | Rs 0.25 crore |
| Market Capitalisation | Rs 49,967.05 crore |
| Market Cap Category | Large Cap |
Ipca Laboratories (IPCALAB) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 49,967.05 crore |
| P/E Ratio | 38.15x |
| P/B Ratio | 5.89x |
| ROE | 15.88% |
| ROCE | 19.41% |
| EPS | Rs 51.63 |
| Book Value Per Share | Rs 334.38 |
| Dividend Yield | 0.3% |
Ipca Laboratories Share Price sits alongside a market capitalisation of Rs 49,967.05 crore, which places the company well above the benchmark median market cap of Rs 732.57 crore for the same industry and below the sector average of Rs 14,043.26 crore only in a comparative sense of distribution, not quality. The company’s P/E ratio is 38.15, compared with the benchmark median of 32.87 and benchmark average of 49.63 across 169 companies with PE data. Its P/B ratio is 5.89 versus the benchmark median of 2.85 and average of 4.33 across 203 companies. ROE is 15.88 and ROCE is 19.41, both above the benchmark medians of 11.48 and 13.17 respectively across 204 companies. EPS is Rs 51.63, book value is Rs 334.38 and dividend yield is 0.3%. These figures provide context for Ipca Laboratories Fundamental Analysis: earnings per share quantify profit attributable to each share, book value per share shows accounting net worth per share, and dividend yield reflects the current payout relationship to price. Univest notes that the stock’s valuation is higher than the industry median on P/E and P/B, while profitability ratios are also above benchmark medians. That combination keeps the fundamentals relevant for anyone reviewing Ipca Laboratories Stock Analysis after today’s decline. The next lens is ownership structure, which can add another layer of context when available.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 38.15x |
| Benchmark Median P/E | 32.87x |
| Benchmark Average P/E | 49.63x |
| Benchmark P/E Range | 3.46x to 735.85x |
| Company P/B Ratio | 5.89x |
| Benchmark Median P/B | 2.85x |
| Benchmark Average P/B | 4.33x |
| Company ROE | 15.88% |
| Benchmark Median ROE | 11.48% |
| Benchmark Average ROE | 10.04% |
| Company ROCE | 19.41% |
| Benchmark Median ROCE | 13.17% |
| Benchmark Average ROCE | 12.82% |
| Company Market Capitalisation | Rs 49,967.05 crore |
| Benchmark Median Market Cap | Rs 732.57 crore |
| Benchmark Average Market Cap | Rs 14,043.26 crore |
The sector backdrop for Ipca Laboratories Share Price is Healthcare, within the Pharmaceuticals & Drugs industry. The benchmark scope covers the same industry with 204 companies, which gives a broad comparison set. Ipca Laboratories’ P/E of 38.15 is above the benchmark median of 32.87 but below the benchmark average of 49.63, showing that the stock sits in the middle-to-upper part of the industry range rather than at an extreme. The company’s P/B of 5.89 is above the benchmark median of 2.85 and average of 4.33, while ROE of 15.88 is above the median 11.48 and average 10.04. ROCE of 19.41 is also above the benchmark median of 13.17 and average of 12.82. The sector benchmark market-cap median is Rs 732.57 crore, the average is Rs 14,043.26 crore, and the largest observed company in the set is Rs 4,44,716.74 crore. In this context, Ipca Laboratories Share Price is being assessed against a broad pharmaceuticals universe that includes firms with much smaller and much larger equity values. That comparison is useful for investors searching Ipca Laboratories Latest News, Ipca Laboratories Market Cap and Ipca Laboratories Share Price News because it shows how the stock’s valuation and profitability metrics sit relative to the same industry set.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,44,716.74 | 36.77 | 5.14 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,55,115.31 | 87.22 | 14.44 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,89,613.38 | 86.94 | 21.13 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,19,899.96 | 26.57 | 4.45 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,12,875.68 | 33.49 | 3.21 | 11.83 | 16 |
Ipca Laboratories Share Price can also be read against listed peers in the same industry. Among the supplied peer set, Sun Pharmaceutical Industries has a market cap of Rs 4,44,716.74 crore, PE of 36.77, PB of 5.14, ROE of 14.85 and ROCE of 19.11, while Divi’s Laboratories shows PE of 87.22 and PB of 14.44. Torrent Pharmaceuticals is higher again on PE at 86.94 and PB at 21.13, with ROE of 26.76. Zydus Lifesciences is at PE 26.57, PB 4.45, ROE 19.69 and ROCE 21.39. Cipla stands at PE 33.49 and PB 3.21, while Dr. Reddy’s Laboratories is at PE 31.16 and PB 2.63. Against that peer set, Ipca Laboratories’ PE of 38.15 and PB of 5.89 are not the highest, but they are above several major names in the group. ROE of 15.88 and ROCE of 19.41 are also competitive versus peers such as Sun Pharmaceutical and Cipla. For readers following Ipca Laboratories Stock News, this peer view helps frame the stock’s valuation and profitability in a practical way without turning today’s decline into a story about cause.
Why Investors Are Watching Ipca Laboratories
- Ipca Laboratories Share Price fell 2.06% to Rs 1,929 after closing below the previous close of Rs 1,969.5.
- The session traded between Rs 1,927.7 and Rs 1,972.95, showing the day’s price range.
- The company’s market capitalisation stands at Rs 49,967.05 crore and the stock is classified as Large Cap.
- PE is 38.15, PB is 5.89, ROE is 15.88, ROCE is 19.41, EPS is Rs 51.63 and book value is Rs 334.38.
- In the Pharmaceuticals & Drugs industry, Ipca Laboratories shares are being compared with Sun Pharma, Divi’s Laboratories, Torrent Pharma, Zydus Lifesciences and Cipla.
About Ipca Laboratories
Ipca Laboratories operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied company profile identifies it through those classifications and places the business in a listed Large Cap context. In today’s Ipca Laboratories Stock News, that company background is relevant because the market is reading the share price alongside sector and peer benchmarks. Univest is presenting the stock through verified market data, valuation metrics and comparative industry context so that readers can place the fall in the right frame. For anyone following Ipca Laboratories Share News or Ipca Laboratories Share Price Live, the company’s identity remains anchored in its listed pharmaceutical profile rather than in any unverified event narrative.
Track Ipca Laboratories Share Price on Univest
Use Ipca Laboratories (IPCALAB) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.
You can track Ipca Laboratories Share Price on Univest for live updates, valuation ratios, shareholding pattern, 52-week levels and company news. Univest also keeps the stock connected to sector context, peer comparison and fundamental ratios so readers can follow Ipca Laboratories Share Price Today in one place. The aim is simple: provide the latest market update, the current stock analysis and the essential numbers in a format that is easy to review.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Ipca Laboratories share price fall today?
Ans. Ipca Laboratories Share Price fell 2.06% to Rs 1,929, but the supplied data does not establish a company-specific catalyst. The article is based on verified price action, valuation and sector comparison only.
What is Ipca Laboratories Share Price today?
Ans. Ipca Laboratories Share Price today is Rs 1,929. It declined from the previous close of Rs 1,969.5 after trading between Rs 1,927.7 and Rs 1,972.95 during the session. The previous close was Rs 1,969.5.
What is Ipca Laboratories market capitalisation?
Ans. Ipca Laboratories has a market capitalisation of Rs 49,967.05 crore and is classified as a Large Cap company. That size context is factual and helps frame the stock’s valuation within the industry.
How does Ipca Laboratories compare with healthcare peers?
Ans. Ipca Laboratories’ PE of 38.15 is above peers such as Zydus Lifesciences at 26.57, Cipla at 33.49 and Dr. Reddy’s at 31.16, while below Divi’s and Torrent on valuation multiples.
What do Ipca Laboratories valuation metrics show?
Ans. Ipca Laboratories has PE of 38.15, PB of 5.89, ROE of 15.88, ROCE of 19.41, EPS of Rs 51.63 and book value of Rs 334.38. These figures help explain the stock’s current market context.
